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A B S T R A C T
Endogenous gaseous mediators, such as nitric oxide, hydrogen sulfide or carbon monoxide (CO) are known to
exert anti-inflammatory and anti-oxidative activity due to modulation of various molecular pahtways.
Therefore, we aimed to investigate if CO released from tricarbonyldichlororuthenium (II) dimer (CORM-2)
prevents gastric mucosa against ischemia/reperfusion (I/R)-induced injury in male Wistar rats. Animals were
pretreated i.g. With vehicle (DMSO and saline, 1:10), CORM-2 (1, 5 or 10mg/kg) or zinc protoporphyrin IX
(ZnPP, 10mg/kg i.p.), the HMOXs inhibitor. In separate series, rats were pretreated with CORM-2 (5mg/kg)
applied in combination with glibenclamide (10 mg/kg i.g.), NG-nitro-L-arginine (L-NNA, 20mg/kg i.p.), 1H-
[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ, 10mg/kg i.p.) or indomethacin (5mg/kg i.p.). I/R-injuries
were induced by clamping celiac artery for 30min (I) followed by removal of the clamp to obtain R for 3 h. The
macroscopic and microscopic area of gastric damage, mucus production and protein expression for HMOX-1/
Nrf-2 was determined by planimetry, histology and immunohistochemistry, respectively. Gastric mucosal
HMOX-1, HMOX-2, COX-1, COX-2, Kir6.1, Sur2, sGC-α1, sGC-α2, iNOS and eNOS mRNA expression was as-
sessed by real-time PCR. COHb in blood and gastric mucosal CO concentration was analyzed by gas chroma-
tography. Serum content of TGF-β1, TGF-β2, TGF-β3, IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, TNF-α, IFN-
γ, GM-CSF was evaluated using Luminex platform. PGE2 concentration and 8-hydroxyguanozine (8-OHG) con-
centration in gastric mucosa was determined by ELISA.
Exposure to I/R induced extensive hemorrhagic erosions in gastric mucosa pretreated with vehicle as com-
pared with intact rats and the area of this gastric damage was reduced by pretreatment with CORM-2 (5mg/kg
i.g.). This effect of CO donor was accompanied by the increased PGE2 content and a significant decrease in 8-
OHG and expression of pro- and anti-inflammatory markers mRNA and proteins. Concurrent treatment of CORM-
2 with glibenclamide, L-NNA, ODQ but not with indomethacin significantly increased the area of I/R-induced
injury and significantly decreased GBF as compared with the group treated with CORM-2 alone.
We conclude that CO releasing CORM-2 prevents gastric mucosal oxidative damage induced by I/R improving
GBF, decreasing DNA oxidation and inflammatory response on systemic level. This CO-gastroprotection is
mediated by the activity of sGC, NOS and K-ATP channels. CO delivered from its donor maintained physiological
gastric mucosal PGE2 concentration but the involvement of endogenous COX in beneficial activity of this gaseous
mediator at least in this model is questionable.
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Recent data has shown that endogenous gaseous mediators, such as
hydrogen sulfide (H2S) or carbon monoxide (CO) are involved, similarly
to nitric oxide (NO) in the maintenance of gastric mucosal integrity and
in the regulation of gastric microcirculation [1–4]. These gas molecules
modulate many cellular pathways and exert anti-inflammatory or anti-
oxidative properties as it has been demonstrated under experimental
conditions in various models of gastrointestinal (GI) pathologies, such
as drugs-induced gastrotoxicity, peptic ulcer healing, stress-induced
gastric damage or experimental colitis [1–3,5–7]. Interestingly, it has
been demonstrated that CO released from its pharmacological donor,
tricarbonyldichlororuthenium (II) dimer (CORM-2) can accelerate
healing of chronic gastric ulcers, possibly due to modulation of various
molecular pathways and growth factors but independently on en-
dogenous H2S biosynthesis [7]. Importantly, CO is produced en-
dogenously via heme degradation by the activity of inducible heme
oxygenase 1 (HMOX-1) and constitutive HMOX-2 [3].
Previous studies demonstrated that CO produced by HMOX or re-
leased from appropriate pharmacological donors has been shown to
ameliorate injury caused by renal, cerebral and myocardial ischemia/
reperfusion (I/R) [8–11]. However, possible gastroprotective effect and
mechanisms of CO releasing from pharmacological donors against I/R-
induced gastric damage has not been fully explained. Therefore, we
aimed to investigate if endogenously produced CO via HMOX-1/Nu-
clear factor (erythroid-derived 2)-like 2 (Nrf-2) or pretreatment with
CO releasing CORM-2 modulates gastric blood flow (GBF) and can
protect the gastric mucosa from gastric lesions induced by I/R and DNA
oxidation on macroscopic, microscopic, biochemical and molecular le-
vels. We focused on the possible involvement of gastroprotective factors
such as endogenous prostaglandin E2 (PGE2) produced by enzymatic
activity of 1) cyclooxygenase (COX)-1 and COX-2, 2) ATP-dependent
potassium channels (K-ATP channels), 3) soluble guanylyl cyclase (sGC)
and inducible or endothelial NO synthases, iNOS and eNOS, respec-
tively, as possible mediators of CO-induced gastroprotection against I/
R-induced gastric damage. Furthermore, we assessed alterations in
gastric mucosal content of CO and COHb concentration in blood of rats
exposed to gastric I/R with or without CORM-2 pretreatment. We have
also determined the contribution of anti-inflammatory properties of CO
in its gastroprotective action against I/R-injury by screening of the
serum concentration profile of 14 pro- and anti-inflammatory factors.
2. Materials and methods
2.1. Experimental design: animals, chemicals and drugs, I/R-injury
Male Wistar rats in the number of 60, with average weight 250–300
g were fasted for 24 h before the experiments with free access to
drinking water. The study was approved by the Institutional Animal
Care and Use Committee of Jagiellonian University Medical College in
Cracow and conducted in accordance with Helsinki Declaration re-
garding handling of experimental animals (Approval no 79/2017,
permission date: 19 July 2017) and run in accordance with the state-
ments of the Helsinki Declaration regarding handling of experimental
animals. Experiments were run with implications for replacement, re-
finement or reduction (the 3Rs) principle. Animal studies are reported
in compliance with the ARRIVE guidelines.
All chemicals and drugs used for in vivo experiments and molecular
or biochemical assessments were purchased from Sigma-Aldrich
(Schnelldorf, Germany) unless otherwise stated.
In the day of experiment, animals of series A were randomized to
the appropriate experimental groups treated i.g. With 1) DMSO and
saline (1:10) as vehicle, 2) CO releasing CORM-2 [7,12], applied in
various doses: 1, 5 or 10mg/kg or 3) zinc protoporphyrin IX (ZnPP), the
HMOXs inhibitor [13], administered i.p. In a dose previously reported
in our studies to decrease CO content in gastric mucosa [14]. In
separate series B, rats were pretreated with CORM-2 alone administered
in a dose of 5mg/kg, selected as the most effective in series An ex-
periments, applied in combination with 1) glibenclamide (10mg/kg
i.g.), inhibitor of K-ATP channels [15], 2) NG-nitro-L-arginine (L-NNA,
20mg/kg i.p.), non-selective NO synthase (NOS) inhibitor [16], 3) 1H-
[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ, 10mg/kg i.p.), sGC
inhibitor [17,18] or 4) indomethacin (5mg/kg i.p.), non-selective COX
inhibitor [18]. All compounds were injected i.p. or administered i.g.
using orogastric tube as reported previously [14]. To decrease the im-
pact of too many confounding factors provided directly to the gastric
mucosa possibly affecting the effectiveness of experimental model,
some agents were applied i.p. If they were originally reported to
maintain its effectiveness on gastric mucosa when administered by this
route [14,16–18]. Exceptionally, glibenclamide was applied i.g. fol-
lowing previously described protocol and because based on previous
reports this route did not affect its effectiveness and it even required
much lower doses of the drug when applied i.g. to evoke desired ex-
perimental effects [15,18–20].
Acute I/R gastric lesions were induced 30min after treatments, as
described previously [21,22]. Briefly, under isofluorane anesthesia, the
abdomen was opened, and the celiac artery was identified and clamped
for 30min of ischemia (I) followed by removal of the clamp to obtain
reperfusion (R) for 3 h.
2.2. Macroscopic assessment of gastric damage area and determination of
GBF level, biological samples collection
After 3 h of R, under isofluorane anesthesia the area of gastric da-
mage was measured by planimetry and the GBF was determined by
laser flowmetry as described previously [18]. Briefly, the GBF was
measured in oxyntic part of the gastric mucosa not involving I/R mu-
cosal lesions using laser flowmeter (Laserflo, model BPM 403A, Blood
Perfusion Monitor, Vasamedics, St. Paul, Minnesota, USA). Average
values of three measurements were determined and expressed in mL/
min per 100 g of gastric tissue. Blood was collected from vena cava and
whole blood or serum samples were stored in −20 °C for further ana-
lyses. The area of I/R-induced gastric damage in each rat stomach was
determined planimetrically and expressed in mm2 [22]. Rats were sa-
crificed by i.p. administration of lethal dose of pentobarbital (Biowet,
Pulawy, Poland). Next, the gastric mucosal samples from oxyntic mu-
cosa were scraped off on ice, snap-frozen in liquid nitrogen and stored
at −80 °C until further analysis [18].
2.3. Microscopic assessment of I/R gastric damage, mucus production and
Nrf-2 and HMOX-1 protein distribution
For histology, the gastric tissue sections were excised and fixed in
10% buffered formalin, pH 7.4. Samples were dehydrated by passing
them through a series of alcohols with incremental concentrations,
equilibrated in xylene for 10–15min and embedded in paraffin; paraffin
blocks were cut into about 4 μm sections using a microtome. The pre-
pared specimens were stained with haematoxylin/eosin (H&E) or alcian
blue/periodic acid-Schiff/alcian blue (AB/PAS) [23].
To evaluate gastric mucosal Nrf-2 and HMOX-1 proteins distribution
within gastric mucosa immunohistochemistry was employed.
Endogenous peroxidase was blocked by 3% H2O2 solution in above-
mentioned specimens and incubated in waterbath in the presence of
EDTA or sodium citrate and treated with proteinase K for 7min. Next,
tissue slides were stained for 30min with anti-HMOX-1 mouse mono-
clonal antibody (1:500; 66743-1-Ig; Proteintech, Manchester, The
United Kingdom) and Nrf-2 rabbit polyclonal antibody (1:200; 16396-
1-AP; Proteintech). BrightVision plus Poly-HRP-Anti MS/Rb IgG system
containing HRP-linked secondary antibody was further implemented.
Next, DAB Quanto (TA-125-QHDX; Thermo Fisher Scientific, Waltham,
MA, USA) was used to visualize investigated proteins in gastric mucosal
tissue sections.
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Samples were evaluated using a light microscope (AxioVert A1, Carl
Zeiss, Oberkochen, Germany) [23]. Digital documentation of histolo-
gical slides was obtained using above mentioned microscope equipped
with automatic scanning table and ZEN Pro 2.3 software (Carl Zeiss,
Oberkochen, Germany) to collect multiple photographs of each histo-
logical sample and to stitch them into one picture; to obtain better
quality of each picture, the background was subtracted and unified as
white [23].
2.4. Determination of CO content in gastric mucosa and blood
carboxyhemoglobin (COHb) concentration using gas chromatography (GC)
CO concentrations in the gastric mucosa biopsies and COHb levels
in whole blood samples were determined as reported previously but
using modified GC based method described in details elsewhere and
briefly below [14,24].
Samples preparation: 10ml of water were added to the tissue
fragments (about 400–600mg) and to the 400 μl of blood sample,
9.6 ml of water and 50mg of sodium thiosulfate were added. Both
samples were homogenized by sonication (Bandelin Sonoplus,
Germany). The volume of 2.5ml of homogenate were pipetted into two
10ml headspace vials (2 test samples). To obtain calibration samples,
about 5ml of the remaining volume of the homogenate was saturated
with CO for 20min (100% saturation CO). The CO used to saturate the
calibration samples was obtained by reacting concentrated sulfuric acid
with 80% formic acid. Unbound CO was removed by flushing with ni-
trogen for 3min. Calibration solutions with CO saturation 1.25; 2.5; 5
and 10% were prepared from 100% saturated homogenates. 2.5 ml of
each calibration solution was pipetted into headspace vials (4 calibra-
tion samples). The vials were then sealed with an aluminum cap and
silicon/Teflon septum. Each vial was gently flushed with helium for
30 s and then 1.5 ml of 20% potassium hexacyanoferridate was added
with a syringe.
GC/O-FID-headspace analysis: for the GC/O-FID-headspace analysis
a Thermo Trace GC Ultra (Thermo Electron Corp. USA) equipped with
O-FID detector (FID with jet nickel microcatalytic methanizer) was
used. The jet nickel microcatalyzer converts CO to methane at 330 °C
which increases the sensitivity of CO detection. The system was
equipped with Thermo TriPlus HS autosampler. The prepared samples
were mixed and incubated at 70 °C for 8min in autosampler agitator to
the achieve a complete CO liberation. 200 μL of gas-phase of each
sample were injected with an autosampler gas-tight syringe (heated at
72 °C). Split/splitess injector (200 °C) with closed split was used. GC
separation was performed with HP-Molesieve column (Agilent
Technologies, USA) 30m/0.53mm ID/0,25 μmat constant flow 15ml/
min of helium as a carrier gas. The temperature program consisted of
the following steps: 60 °C for 2min followed by 120 °C for 2min
achieved by a heating rate 60 °C/min.
2.5. Determination of mRNA expression for HMOX-1, HMOX-2, COX-1,
COX-2, Kir6.1, Sur2, sGC-α1, sGC-α2, iNOS and eNOS in gastric mucosa by
real-time polymerase chain reaction (PCR)
Gastric mucosal mRNA expression for HMOX-1, HMOX-2, COX-1,
COX-2, Kir6.1, Sur2, sGC-α1, sGC-α2, iNOS and eNOS was determined
by real time PCR, as described previously [23]. Total RNAwas isolated
using commercially available kit with spin columns (GeneMATRIX
Universal RNA Purification Kit, EURx, Gdansk, Poland) according to
manufacturer protocol. Reversed transcription to cDNA was performed
using High-Capacity cDNA Reverse Transcription Kit (MultiScribe™,
Applied Biosystems, Life Technologies, Carlsbad, CA, USA) and random
primers.
RNA concentration was measured using Qubit 4 Fluorometer
(Thermo Fisher Scientific, Waltham, MA, USA). RT was normalized for
each reaction regarding total RNA concentration to obtain the same
value (2 μg) for each sample. Results obtained for RNA samples isolated
from healthy (intact) gastric mucosa and transcribed to cDNA were
further used as reference control during calculations.
Expression for HMOX-1, HMOX-2, COX-1, COX-2, iNOS, eNOS and
B-actin and succinate dehydrogenase complex (SDHA) as reference
genes was determined using specific primers [23]. Kir6.1 was de-
termined using 5′- TGGAGAAAGGCATCACGGAG-3′ forward and 5′-
AACGCAGAAGTGAATGACCTGA-3′ reverse primers. Sur2 was de-
termined using 5′-GCCATAAAGGTGACGAACGG-3′ forward and
5′-GACGATTTGCCACAACCCAC-3′ reverse primers. sGC-α1 was de-
termined using 5′- TCATCACCATGCTCAACGCT-3′ forward and
5′-TCCGATGGTCTCCACCTTGT-3′ reverse primers. sGC-α2 was de-
termined using 5′-GTTGCATCAGGGCTTCACAG-3′ forward and 5′-ATC
CGCATCTGAATGGGTCTT-3′ reverse primers.
Real-time PCR was conducted using thermal cycler Quant Studio 3
(Thermo Fisher Scientific, Waltham, MA, USA) and SYBR Green dye
including kit (SG qPCR Master Mix (2x), EURx, Gdansk, Poland).
Results were analyzed using ΔΔCt method [23,25].
2.6. Measurement of serum content of pro- and anti-inflammatory factors
by luminex microbeads fluorescent assays
Determination of TGF-β1, TGF-β2, TGF-β3, IL-1α, IL-1β, IL-2, IL-4,
IL-5, IL-6, IL-10, IL-12, TNF-α, IFN-γ, GM-CSF concentrations in serum
was performed using Luminex micro beads fluorescent assays (Bio-Rad,
California, USA) and Luminex MAGPIX System (Luminex Corp., Austin,
TX, USA). Results were calculated from calibration curves and ex-
pressed in pg/ml, according to the manufacturers protocol, as described
previously [7].
2.7. Determination of PGE2 and 8-hydroxyguanozine (8-OHG)
concentration in gastric mucosa
PGE2 concentration in gastric mucosal samples obtained from ulcer
margin was determined using PGE2 ELISA kit (ab133021, Abcam) ac-
cording to manufacturer's protocol. Homogenization process of each
sample was standarized regarding sample weight and buffer volume
and results were expressed in pg/ml of gastric tissue homogenate. 8-
OHG content as DNA oxidation marker was assessed in DNA isolated
from gastric mucosa using ELISA kit (589320, Cayman Chemical, Ann
Arbor, MI, USA) according to manufacturer's protocol.
2.8. Statistical analysis
Experiments and data collection were done by operators blinded to
the sample identity. Results were analyzed using GraphPad Prism 5.0
software (GraphPad Software Inc., La Jolla, CA, USA). Results are
presented as mean ± SEM. Statistical analysis was conducted using
Student's t-test or ANOVA with Dunnett's multiple comparison or
Tukey's post hoc test if more than two experimental groups were
compared. The size for each experimental group was of n= 5–6.
P < 0.05 was considered to be statistically significant.
3. Results
3.1. Gastroprotective and hyperemic effects of CO releasing CORM-2
against I/R-induced gastric damage, mucus production and modulation of
HMOX-1 and Nrf-2 protein distribution
Fig. 1A and B shows the mean area of I/R-induced gastric damage
and changes in GBF, respectively, in rats pretreated with vehicle,
CORM-2 (1–10mg/kg i.g.) or ZnPP (10mg/kg i.p.). CORM-2 adminis-
tered in a dose of 1mg/kg or 5mg/kg but not 10mg/kg, significantly
decreased the area of I/R gastric damage and significantly increased
GBF as compared with vehicle-treated animals (p < 0.05) (Fig. 1A–B).
Pretreatment with ZnPP did not affect significantly mean gastric da-
mage area and GBF as compared with vehicle (Fig. 1A and B).
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Pretreatment with CORM-2 combined with glibenclamide (10mg/
kg i.g.), L-NNA (20mg/kg i.p.) or ODQ (10mg/kg i.p.) but not with
indomethacin (5mg/kg i.p.) significantly increased the area of gastric
I/R lesions and significantly decreased GBF as compared with rats
treated with CORM-2 alone (p < 0.05) (Fig. 1C and D). When ODQ
was co-administered with CORM-2 a significant decrease in area of
gastric I/R damage as compared with the vehicle-treated animals was
observed (p < 0.05) (Fig. 1C).
As shown in Fig. 1E, the exposure of gastric mucosa to I/R induced
extensive hemorrhagic erosions in gastric mucosa pretreated with ve-
hicle (arrows) as compared with intact rats and the area of this lesions
was significantly reduced in rats pretreated with CORM-2 (5mg/kg i.g.)
vs vehicle. Fig. 1F shows representative histology photomicrographs of
intact (control) gastric mucosa and gastric mucosa pretreated with
vehicle or CORM-2 (5mg/kg i.g.) and exposed to I/R. Alterations in
microscopic appearance, mucus production, HMOX-1 and Nrf-2 protein
expression in gastric mucosa was demonstrated using H/E, AB/PAS and
IHC staining, respectively (Fig. 1F). I/R induced necrotic erosions of
surface epithelium penetrating deeply into gastric mucosa reaching
lamina propria with submucosal leukocytes infiltration as compared
with intact rats (intact vs vehicle; H/E; Fig. 1F). These alterations were
accompanied by the disruption of mucus layer of surface epithelium
and decreased yield of HMOX-1 and Nrf-2 expression within damaged
part of gastric mucosa (intact vs vehicle; AB/PAS, HMOX-1, Nrf-2;
Fig. 1F). Pretreatment with CORM-2 limited the histologic injury of I/R-
induced erosions to the superficial epithelium but failed to affect the
Fig. 1. Mean lesion area (A, C) and the gastric blood flow (GBF) (B, D) in intact (control) gastric mucosa and in gastric mucosa of rats pretreated with vehicle or
tricarbonyldichlororuthenium(II) dimer (CORM-2, 5mg/kg i.g.) alone or in combination with glibenclamide (10mg/kg i.g.), NG-nitro-L-arginine (L-NNA, 20mg/kg
i.p.), 1H- [1,2,4]oxadiazolo [4,3-a]quinoxalin-1-one (ODQ, 10mg/kg i.p.), indomethacin (5mg/kg i.p.) and exposed to 3.5 h of ischemia/reperfusion (I/R). Intact
refers to healthy gastric mucosa not exposed to I/R. ZnPP refers to the group pretreated with zinc protoporphyrin IX (10mg/kg i.p.) and exposed to I/R. Results are
mean ± S.E.M of 5 rats per each experimental group. Significant change as compared with the respective values in vehicle-control group is indicated by asterisk
(p < 0.05). Double asterisk indicates significant change as compared with the respective values in rats pretreated with vehicle and CORM-2 administered in a dose of
1 mg/kg (p < 0.05). Cross indicates significant change as compared with the respective values in rats pretreated with CORM-2 alone (p < 0.05). Significant change
as compared with the GBF values in intact rats is indicated by hash (p < 0.05). E: Macroscopic appearance of randomly selected representative gastric mucosa
exposed or not to I/R; gastric mucosal injuries pointed by yellow arrows. F: Randomly selected representative histological slides of gastric mucosa exposed or not to I/
R with or without vehicle or CORM-2 pretreatment and stained with H/E, PAS/AB or anti-HMOX-1 or anti-Nrf-2 antibodies; gastric injuries pointed by yellow arrows.
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decrease in mucus production and HMOX-1 and Nrf-2 expression within
these injurious sites of gastric mucosa (vehicle vs CORM-2; H/E, AB/
PAS, HMOX-1, Nrf-2; Fig. 1F).
3.2. Alterations in HMOX-1, HMOX-2 mRNA expression and in CO content
in gastric mucosa and blood COHb concentration of rats exposed to I/R and
pretreated or not with CORM-2
Fig. 2A–B shows that HMOX-1 (A) but not HMOX-2 (B) mRNA ex-
pression in gastric mucosa with I/R-induced gastric damage was sig-
nificantly increased as compared with the respective values in intact
gastric mucosa (p < 0.05) (Fig. 2A–B). Pretreatment with CORM-2
significantly increased mRNA expression of HMOX-1 but not HMOX-2
as compared with the vehicle-control group (p < 0.05) (Fig. 2A–B).
CO saturation of gastric mucosa with I/R-induced gastric damage
was not significantly affected as compared with intact gastric mucosa
(p < 0.05) (Fig. 2C). Pretreatment with CORM-2 significantly in-
creased gastric mucosal CO content as compared with the vehicle-
control group (p < 0.05) (Fig. 2C). The blood COHb concentration was
not significantly affected in rats with I/R-induced gastric damage as
compared with intact animals (p < 0.05) (Fig. 2D). Pretreatment with
CORM-2 significantly increased blood concentration of COHb as com-
pared with the vehicle-control group (p < 0.05) (Fig. 2D).
3.3. The changes in COX-1 and COX-2 mRNA expression and PGE2 content
in gastric mucosa exposed to I/R and pretreated or not with CORM-2
Fig. 3A–B shows that COX-1 (A) and COX-2 (B) mRNA expression in
gastric mucosa with I/R-induced gastric damage was not significantly
affected as compared with the respective values in intact gastric mucosa
(Fig. 3A–B). Pretreatment with CORM-2 did not affect mRNA expres-
sion of COX-1 or COX-2 as compared with the vehicle-control group
(Fig. 3A–B).
PGE2 concentration in gastric mucosa with I/R-induced gastric da-
mage was significantly decreased as compared with intact gastric mu-
cosa (p < 0.05) (Fig. 3C). Pretreatment with CORM-2 significantly
increased gastric mucosal PGE2 content as compared with the vehicle-
control group (p < 0.05) (Fig. 3C).
Fig. 2. Heme oxygenase (HMOX)-1 and 2 mRNA expression and CO saturation in gastric mucosa and the concentration COHb in blood of rats pretreated with vehicle
or tricarbonyldichlororuthenium(II) dimer (CORM-2, 5 mg/kg i.g.) and exposed to 3.5 h of ischemia/reperfusion (I/R). Intact refers to healthy gastric mucosa not
exposed to I/R. Results are mean ± S.E.M of 5 samples per each experimental group. A and B: results are expressed as fold change of normalized gastric mucosal
HMOX-1 and HMOX-2 mRNA expression; red line refers to the baseline expression in intact gastric mucosa. C and D: results are expressed as % of CO saturation of
gastric mucosa or COHb concentration in blood, respectively. Asterisk indicates a significant change as compared with respective values obtained in intact group
(p < 0.05). Cross indicates a significant change as compared with the values obtained in the vehicle-pretreated group exposed to I/R (p < 0.05). A and B: statistical
significance was marked only if 2-fold up- or downregulation was reached.
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3.4. Alterations in mRNA expression of K-ATP channels subunits, Kir6.1
and Sur2 and sGC-α1 and α2 subunits in gastric mucosa exposed to I/R with
or without pretreatment with CORM-2
Fig. 4 shows that Kir6.1 (A) and Sur2 (B) mRNA expression in
gastric mucosa with I/R-induced gastric damage was significantly
downregulated as compared with the respective values in intact gastric
mucosa (p < 0.05) (Fig. 4A–B). Pretreatment with CORM-2 did not
affect mRNA expression of Kir6.1 or Sur2 as compared with the vehicle-
control group (Fig. 4A–B). Fig. 4 shows that sGC-α1 (C) and α2 (D)
mRNA expression in gastric mucosa with I/R-induced gastric damage
was significantly downregulated as compared with the respective va-
lues in intact gastric mucosa (p < 0.05) (Fig. 4C–D). Pretreatment with
CORM-2 did not affect mRNA expression of Kir6.1 or Sur2 as compared
with the vehicle-control group (Fig. 4C–D).
3.5. The effect of pretreatment with CORM-2 on mRNA expression of NOS
isoforms, iNOS and eNOS in gastric mucosa exposed to I/R
Fig. 5 shows that iNOS (A) but not eNOS (B) mRNA expression was
significantly upregulated in gastric mucosa with I/R-induced gastric
damage as compared with the respective values in intact gastric mucosa
(p < 0.05) (Fig. 5A and B). Pretreatment with CORM-2 significantly
decreased mRNA expression of iNOS (A) but not eNOS (B) as compared
with the vehicle-control group (p < 0.05) (Fig. 5A and B).
3.6. Oxidative DNA damage in gastric mucosa exposed to I/R pretreated
with vehicle or CORM-2
Fig. 6 shows that 8-OHG content was significantly upregulated in
gastric mucosa with I/R-induced gastric damage as compared with the
respective values in intact gastric mucosa (p< 0.05). Pretreatment
with CORM-2 significantly decreased 8-OHG content as compared with
the vehicle-control group (p<0.05) (Fig. 6).
3.7. The effect of pretreatment with vehicle or CORM-2 on pro- and anti-
inflammatory cytokines concentration in serum of rats exposed to I/R
Fig. 7A-N shows that exposure to I/R significantly increased con-
centration of TGF-β2 (B), TGF-β3 (C), IL-1α (D), IL-1β (E), IL-2 (F), IL-4
(G), IL-5 (H), IL-6 (I), IL-10 (J), IL-12 (K), TNF-α (L), IFN-γ (M), GM-CSF
(N) but not TGF-β1 (A) in serum as compared with intact rats
Fig. 3. Cyclooxygenase (COX)-1 and COX-2 mRNA expression in gastric mucosa of rats pretreated with vehicle or tricarbonyldichlororuthenium(II) dimer (CORM-2,
5 mg/kg i.g.) and exposed to 3.5 h of ischemia/reperfusion (I/R). Intact refers to healthy gastric mucosa not exposed to I/R. Results are mean ± S.E.M of 5 samples
per each experimental group. A and B: results are expressed as fold change of normalized gastric mucosal COX-1 and COX-2 mRNA expression; red line refers to the
baseline expression in intact gastric mucosa. A and B: statistical significance was marked only if 2-fold up- or downregulation was reached. C: results are expressed as
PGE2 level in gastric mucosa. Asterisk indicates a significant change as compared with respective values obtained in intact group (p < 0.05). Cross indicates a
significant change as compared with the values obtained in the vehicle-pretreated group exposed to I/R (p < 0.05).
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Fig. 4. Gastric mucosal mRNA expression of ATP-dependent potassium channels subunits Kir6.1 (A) and Sur2 (B) and soluble guanylyl cyclase (sGC)-α1 (C) and sGC-
α2 (D) subunits, determined in rats pretreated with vehicle or tricarbonyldichlororuthenium(II) dimer (CORM-2, 5mg/kg i.g.) and exposed to 3.5 h of ischemia/
reperfusion (I/R). Intact refers to healthy gastric mucosa not exposed to I/R. Results are mean ± S.E.M of 5 samples per each experimental group with statistical
significance marked only if 2-fold up- or downregulation was reached. Results are expressed as fold change of normalized gastric mucosal Kir6.1, Sur2, sGC-α1 and
sGC-α2 mRNA expression. Asterisk indicates a significant change as compared with respective values obtained in intact group (p < 0.05).
Fig. 5. Expression of iNOS (A) and eNOS (B) mRNA in gastric mucosa of rats pretreated with vehicle or tricarbonyldichlororuthenium(II) dimer (CORM-2, 5 mg/kg
i.g.) and exposed to 3.5 h of ischemia/reperfusion (I/R). Results are mean ± S.E.M of 5 samples per each experimental group with statistical significance marked
only if 2-fold up- or downregulation was reached. Results are expressed as fold change of normalized gastric mucosal iNOS and eNOS mRNA expression. Asterisk
indicates a significant change as compared with respective values obtained in intact gastric mucosa, not exposed to I/R (p < 0.05). Cross indicates a significant
change as compared with the values obtained in the vehicle-pretreated group exposed to I/R (p < 0.05).
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(p < 0.05). Pretreatment with CORM-2 significantly decreased TGF-β3
(C), IL-1α (D), IL-1β (E), IL-2 (F), IL-4 (G), IL-5 (H), IL-6 (I), IL-10 (J),
IL-12 (K), TNF- α (L), IFN-γ (M), GM-CSF (N) but not TGF-β1 (A) or
TGF-β2 (B) concentrations in serum or rats exposed to I/R as compared
with vehicle-control group (p < 0.05) (Fig. 7A-N).
4. Discussion
Previous studies have demonstrated that the exposure to I/R led to
induction of reactive oxygen species (ROS) generation from xanthi-
ne–xanthine oxidase system and an increase in tissue lipid peroxidation
due to activated neutrophils, resulting in gastric mucosal hemorrhagic
lesions [26–29]. We have documented in this study that pretreatment
with CORM-2 increased gastric mucosal CO content, raised GBF and the
mRNA expression for HMOX-1 resulting in gastroprotection against the
formation of I/R-induced gastric damage and DNA oxidation. More-
over, we observed that exposure to I/R upregulated gastric mucosal
mRNA expression of HMOX-1, involved in endogenous production of
CO. However, within I/R-injured parts of gastric epithelium, the ex-
pression of HMOX-1 and Nrf-2 proteins were not detectable. This is in
pair with previously published data showing that HMOX-1 mRNA ex-
pression was increased in various experimental models of oxidative and
inflammatory injury [3]. Additionally, it has been shown previously
that administration of CORM-2 under pathological conditions even
enhanced HMOX-1 mRNA expression [14,23,30], suggesting that this
enhancement could be due to positive feedback mechanism. Possibly,
pretreatment with CO donor enhanced self-defence gastric mucosal
response against I/R injury manifested as upregulation of HMOX-1
mRNA expression.
Interestingly, gastroprotective effect of CORM-2 was dose-depen-
dent to certain degree because when applied in a dose of 10mg/kg this
CO-donor did not exert protection against I/R-damage. Indeed, pre-
vious report documented that pretreatment with CO donor adminis-
tered i.g. In higher dose, 50mg/kg exacerbated ethanol-induced gastric
mucosal erosions [30]. This suggests that increased bioavailability of
CO is beneficial to gastric mucosa but when a threshold concentration
of this gas in the tissue is exceeded, its cytotoxicity under specific
pathological conditions can occur. Our finding on CO-induced gastro-
protection against I/R injury paralleled our previous observations that
CO-releasing chemicals prevented stress-induced gastric lesions and
those evoked by i.g. administration of ethanol or alendronates
[14,23,31–34]. Our present data in experimental model of I/R is cor-
roborative with previous observations that HMOX-1 and CO releasing
CORM-2 or CORM-3 ameliorated I/R-induced damage to the liver or
skeletal muscles [35–38].
I/R-injuries were shown to progress with longer time into chronic
ulcerations [39]. It has been previously reported that CORM-2-medi-
ated healing of chronic gastric ulcers was diminished by combined
treatment of this CO-donor with non-selective COX-1 and COX-2 in-
hibitor, indomethacin, administered daily through 9 days after ulcer
induction [18]. Interestingly, in our study we have observed that I/R-
induced decrease in mucosal PGE2 content was reversed by pretreat-
ment with this CO donor. However, the mRNA expression of COX-1 or
COX-2 was not affected in gastric mucosa with or without pretreatment
with CORM-2. Furthermore, CO donor was still effective in protection
of gastric mucosa against I/R-damage despite the presence of in-
domethacin. Therefore, we assume that CO released from CORM-2
could bind to heme domain and as result, it could affect COX activity
even during exposure to I/R, thus maintaining the gastric mucosal PGE2
production. However, at least in this model of gastric injury, CO seems
to exert its gastroprotective activity independently on PGE/COX
system.
We have demonstrated that pharmacological inhibition of K-ATP
channels by glibenclamide completely reversed CORM-2-mediated
gastric hyperemia and gastroprotection against I/R injury. Moreover,
pretreatment with CO donor did not affect decreased mRNA expression
for K-ATP channels subunits, Kir6.1 and Sur2. This is corroborative
with previous observation that glibenclamide decreased CO effect on
Cl− and HCO3- anions secretion in rats colon tissue [40]. Furthermore,
Soni et al. revealed that CORM-2 reduces I/R injury in Langendorff's
perfused rat hearts and that this cardioprotective effect of CO donor
was reversed by K-ATP channels inhibition [41]. Therefore, we assume
that CO-mediated protection against I/R injuries involves K-ATP
channels activity, possibly due to activation of heme binding domain
Sur 2A by this gaseous mediator [42].
Furthermore, the pharmacological inhibition of NOS and sGC ac-
tivity also reversed and reduced, respectively CORM-2-mediated gas-
troprotection against I/R injury and accompanying elevation of GBF.
This is in pair with previously published data showing that ulcer
healing effect of CO donor was attenuated by NOS blockade by L-NNA
and inhibition of sGC activity by ODQ [18]. Interestingly, in this study
we have observed that pretreatment with CORM-2 remained without
effect on gastric mucosal mRNA expression of sGC-α1 and α2 subunits,
both downregulated in gastric mucosa of rats exposed to I/R. We as-
sume that CO-induced increase in GBF was dependent on NOS and
partly mediated by sGC activity, both containing heme-binding do-
mains [43,44].
Interestingly, mRNA expression for eNOS was not affected by I/R in
gastric mucosa pretreated or not with CORM-2. However, mRNA ex-
pression of pro-inflammatory iNOS was upregulated within damaged
tissue and pretreatment with CO donor decreased this mRNA fold
change. Furthermore, exposure to I/R increased serum concentration of
pro- and anti-inflammatory markers such as TGF-β2, TGF-β3, IL-1α, IL-
1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, TNF-α, IFN-γ, GM-CSF and pre-
treatment with CORM-2 reversed this effect. Also, CO donor prevented
I/R-induced DNA oxidation. Moreover, anti-inflammatory and anti-
oxidative effect of CO has been reported previously [3]. Therefore, our
results confirmed strong anti-inflammatory and anti-oxidative effect of
CO released from CORM-2 as a part of the complex gastroprotective
mechanism induced by this gaseous molecule.
Fig. 6. Gastric mucosal 8-hydroxyguanozine (8-OHG) concentration de-
termined in rats pretreated with vehicle or tricarbonyldichlororuthenium(II)
dimer (CORM-2, 5 mg/kg i.g.) and exposed to 3.5 h of ischemia/reperfusion (I/
R). Intact refers to healthy gastric mucosa not exposed to I/R. Results are
mean ± S.E.M of 5 samples per each experimental group. Results are expressed
as 8-OHG concentration standarized to 1 μg of total DNA per each sample.
Asterisk indicates a significant change as compared with respective values ob-
tained in intact group (p < 0.05). Cross indicates a significant change as
compared with respective values obtained in group pretreated with vehicle and
exposed to I/R (p < 0.05).
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5. Conclusions
Taken together, we conclude that the CO/HMOX-1/Nrf-2 patway is
involved in the mechanism of I/R-induced gastric mucosal damage
(Fig. 8). It is not excluded that the increase in mRNA expression for
HMOX-1 ocurred possibly due to a positive defensive feedback me-
chanism in response to damaging effect of I/R. The pretreatment with
CO releasing CORM-2 which increased both, the gastric mucosal CO
content and COHb concentration resulting in enhancement in gastric
microcirculation attenuated gastric lesions induced by I/R while de-
creased gastric DNA oxidation and inflammatory response at the sys-
temic level as reflected by profound inhibition of proinflammatory
cytokines. This CO-gastroprotection was mediated by the activity of
sGC, NOS and K-ATP channels without affecting the mRNA expression
of ATP-dependent potassium channels subunits Kir6.1 and Sur2 and
soluble guanylyl cyclase (sGC)-α1 and sGC-α2 subunits. CO delivered
from its donor maintained physiological gastric mucosal PGE2 con-
centration but in contrast to our previous observation with CORM-2-
induced gastroprotection against “contact” mucosal injury evoked by
intragastric ethanol application which became reversible by in-
domethacin [30], the involvement of mRNA expression of either COX-1
or COX-2 in beneficial activity of this gaseous mediator at least in this
model of microcirculatory perturbations, has not been observed.
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